Wuxi Apptec (药明康德) Placement: Well-Flagged Deal in the Hot Sector
Wuxi Apptec launched a USD 950 million placement after it obtained CSRC approval for its proposed A+H placement today after market close. We have...
573 Views
Tigermed (泰格医疗) A+H: Past A+H Listings Suggest Upside Might Be Limited
Tigermed, the largest China-based clinical CRO company, launched book building today to raise up to USD 1.4 bn to list in Hong Kong. In our...
539 Views
Tigermed IPO: Valuation Insights
Hangzhou Tigermed Consulting (H) (3347 HK) is a global contract research organisation (CRO). Tigermed is the largest clinical CRO in China with a...
536 Views
China AH Premium: Trade Ideas As We Near Previous Highs
The Hang Seng Stock Connect China AH Premium Index (HSAHP) measures the absolute price premium or discount of A-shares over H-shares for the...
828 Views
Tigermed (泰格医疗) A+H: PHIP Updates and Thoughts on Valuation
Hangzhou Tigermed, a leading China-based CRO company, is seeking a USD 1.5 bn H-share listing in Hong Kong. In our previous note, we discussed that...
613 Views